Genitourinary cancers
On The Go
Short upright videos. Tap one to watch, then swipe for the next.
LITESPARK-011: Belzutifán + Lenvatinib mejora la supervivencia libre de progresión | ESMO 2026
Dr. Natalia Gandur
VOLGA: Durvalumab + Enfortumab Vedotin mejora la supervivencia en cáncer de vejiga | ESMO 2026
Dr. Natalia Gandur
PEACE-1: Abiraterona mejora la supervivencia en cáncer de próstata metastásico | ESMO 2026
Dr. Natalia Gandur
DASL-HiCaP: Darolutamida melhora a sobrevida livre de metástases no câncer de próstata | ESMO 2026
Can triplet combinations improve outcomes in advanced urothelial cancer?
Sara Coca Membribes
LIVE from Lugano
OncoAlert Together with the Advanced Prostate Cancer Consensus Conference have created the Live from Lugano series capturing the discussions Live from the APCCC26 meeting in Lugano Switzerland

IRONMAN: building a global prostate cancer cohort
Dr. Ian Davis and Dr. Alicia Morgans
November 8, 2026. 4 minutes.

Breaking down barriers to prostate cancer care in Nigeria
November 8, 2026. 5 minutes.

Why prostate cancer outcomes differ across the UK
November 8, 2026. 5 minutes.

The role of statins in prostate cancer
Dr. Anthony Joshua and Dr. Noel Clarke and Dr. Lisa Horvath
November 8, 2026. 5 minutes.

Managing urinary incontinence in prostate cancer patients
Dr. Erik Briers and Dr. Noel Clarke and Dr. Nicola Fossati
November 8, 2026. 5 minutes.

Assessing the risk of incontinence before prostate cancer treatment
Dr. Erik Briers and Dr. Noel Clarke and Dr. Nicola Fossati
November 8, 2026. 5 minutes.

Support resources for prostate cancer patients and partners
Dr. Stacy Loeb and Brian Jones
November 8, 2026. 3 minutes.

Why sexual health must be part of the conversation in prostate cancer
Dr. Stacy Loeb and Brian Jones
November 8, 2026. 2 minutes.

The broader impacts of prostate cancer on sexual health
Dr. Stacy Loeb and Brian Jones
November 8, 2026. 3 minutes.

EMPRO: making prostate cancer research more patient-centered
Dr. Ian Davis and Dr. Alicia Morgans
November 8, 2026. 6 minutes.

EMPRO: bringing patient-reported outcomes into care
Dr. Ian Davis and Dr. Alicia Morgans
November 8, 2026. 5 minutes.

Older patients: when more is more, and when less is more
Dr. Dana Rathkopf and Dr. Bertrand Tombal
November 8, 2026. 4 minutes.

Older patients: age, toxicity and de-escalation
Dr. Dana Rathkopf and Dr. Bertrand Tombal
November 8, 2026. 4 minutes.

Beyond chronological age: optimizing therapy in older patients
Dr. Dana Rathkopf and Dr. Bertrand Tombal and Dr. Christopher Sweeney
November 8, 2026. 4 minutes.


The evidence for exercise in prostate cancer
Dr. Charles Ryan and David Matheson
November 8, 2026. 4 minutes.

Why lifestyle changes matter after a prostate cancer diagnosis
Dr. Charles Ryan and David Matheson and Dr. Christopher Sweeney
November 8, 2026. 7 minutes.

Triplet vs doublet therapy in metastatic hormone-sensitive prostate cancer
November 8, 2026. 5 minutes.

Balancing quality of life: radiotherapy after prostatectomy
Dr. Jochen Walz and Dr. Piet Ost and Dr. Erik Briers
November 8, 2026. 5 minutes.

Overtreatment in biochemical recurrence: the patient perspective
Dr. Jochen Walz and Dr. Piet Ost and Dr. Erik Briers
November 8, 2026. 3 minutes.

Adjuvant vs salvage radiotherapy after prostatectomy
Dr. Jochen Walz and Dr. Piet Ost and Dr. Erik Briers
November 8, 2026. 5 minutes.

Shaping the future of high-risk prostate cancer
Dr. Bertrand Tombal and Dr. Jason Efstathiou and André Deschamps
November 8, 2026. 4 minutes.

Prostate cancer: understanding the patient experience
Dr. Bertrand Tombal and Dr. Jason Efstathiou and André Deschamps
November 8, 2026. 5 minutes.

Optimizing treatment selection for high-risk localized prostate cancer
Dr. Bertrand Tombal and Dr. Jason Efstathiou and André Deschamps
November 8, 2026. 3 minutes.

Clinical application of biomarkers in localized prostate cancer
Dr. Bertrand Tombal and Dr. Christopher Sweeney and Dr. Jeff Michalski
November 8, 2026. 2 minutes.

Defining the right endpoints for ARPI intensification
Dr. Bertrand Tombal and Dr. Christopher Sweeney and Dr. Jeff Michalski
November 8, 2026. 3 minutes.
Podium2Screen
Podium2Screen videos on genitourinary cancers, newest first.
-e6d6a8d836.png&w=3840&q=75)
More is not always better in kidney cancer: LITESPARK-012 at #ESMO26
Dr. Toni Choueiri
October 29, 2026.


Adjuvant pembrolizumab remains the standard for high-risk ccRCC. Final OS Analysis of KEYNOTE 564
Dr. Toni Choueiri
October 29, 2026.

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26
Dr. Daniel Heng
October 28, 2026.

Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026
Dr. Andrea Necchi
October 28, 2026.

VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
Dr. Tom Powles
October 28, 2026.
Highlights
Regulatory news and paper picks on genitourinary cancers, newest first.
Videos
Round-ups, expert picks and interviews on genitourinary cancers, newest first.
Oncology Here & Now
The podcast: short conversations, one tumor type at a time.
Prostate cancer statistics 2025Dr. Gil Morgan and Mr. Tyler KratzerSeason 2, Episode 2, September 25, 2025
The BULLSEYE trial and PSMA radioligandsDr. Danny Mena and Dr. Barbara MelãoSeason 2, Episode 1, September 7, 2025
Upper tract urothelial carcinomaDr. Philippe Spiess and Dr. Barbara MelãoSeason 1, Episode 6, May 20, 2025
The Advanced Prostate Cancer Consensus ConferenceDr. Silke Gillessen and Dr. Aurelius OmlinSeason 1, Episode 1, March 5, 2025

From the Colloquium
The genitourinary cancers day of the sixth OncoAlert Colloquium, February 2026: 8 talks.
State-of-the-art management and controversies across GU malignancies, integrating medical oncology, surgery, radiotherapy, diagnostics and advocacy.
Moderated by Dr. Natalia Gandur and Dr. Gil Morgan.
Kidney cancerDr. Brian Rini. Uromigos session
Bladder cancerDr. Tom Powles. Uromigos session
Prostate cancerDr. Silke Gillessen. APCCC session
Urology reviewDr. Declan Murphy and Dr. Renu Eapen. GU Cast
DiagnosticsDr. Juan Antonio Vallejo. GUARD
GU radiotherapyDr. Sean McBride
AdvocacySalvo LaRosa. Kidney Cancer Association
How I treat when options are limitedDr. Natalia Gandur
Faculty
The OncoAlert faculty for genitourinary cancers, in a new order on every visit.

Dr. Neeraj Agarwal
Huntsman Cancer Institute, Utah
Genitourinary cancers

Dr. Laurence Albiges
Gustave Roussy

Dr. Andrea Apolo
National Cancer Institute (NCI)
Genitourinary cancers

Dr. Daniel Castellano
Hospital 12 de Octubre, Madrid
Genitourinary cancers

Dr. Toni Choueiri
Dana-Farber / Harvard
Genitourinary cancers

Dr. Eleni Efstathiou
Houston Methodist Cancer Center
Genitourinary cancers

Dr. Bishoy Faltas
Weill Cornell Medicine
Genitourinary cancers

Dr. Silke Gillessen
Univ. of Manchester / The Christie
Genitourinary cancers

Dr. Petros Grivas
UW Medicine
Genitourinary cancers

Dr. Hans Hammers
UT Southwestern Medical Center
Genitourinary cancers

Dr. Daniel Heng
Tom Baker Cancer Center, Calgary
Genitourinary cancers

Sara Coca Membribes
Genitourinary cancers

Dr. Axel Merseburger
University Hospital Schleswig-Holstein
Genitourinary cancers

Dr. Declan Murphy
Peter MacCallum Cancer Centre
Genitourinary cancers

Dr. Andrea Necchi
San Raffaele Hospital and Scientific Institute
Genitourinary cancers

Dr. Aurelius Omlin
Cantonal Hospital St. Gallen, Switzerland
Genitourinary cancers

Dr. Sumanta Pal
City of Hope
Genitourinary cancers

Dr. Tom Powles
Barts Cancer Centre, London
Genitourinary cancers

Dr. Brian Rini
Vanderbilt-Ingram Cancer Center
Genitourinary cancers

Dr. Tian Zhang
Duke Cancer Institute
Genitourinary cancers



